Vivani is a pre-clinical-stage developer of long-term pharmaceutical implants aimed at revolutionizing the treatment of patients with chronic diseases. Leveraging its proprietary NanoPortal™ platform, Vivani’s portfolio of tiny, sub-dermal drug implants address medication non-adherence by providing steady levels of medication over a target duration of six months or longer. Vivani is developing two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide). In addition, the company is developing NPM-119, a lower dose exenatide implant for the treatment of type 2 diabetes.
The company, Vivani Medical, was founded in 1998 and operates in the Health Care, Manufacturing, and Medical Devices industries. The latest investment was a post-IPO equity investment on 01 March 2024, however, the details of the investors were not disclosed.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 01 Mar 2024 | |
| Grant | Unknown | - | 04 Apr 2023 | |
| Grant | Unknown | - | 18 Jul 2022 | |
| Post-IPO Equity | Unknown | - | 25 Jun 2021 | |
| Grant | Unknown | - | 01 Oct 2019 |
No recent news or press coverage available for Vivani.
We care about your data, and we'd love to use cookies make your experience better.
